Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options.